Oncolytic Immunotherapy

The concept of using targeted oncolytic viruses for cancer has been around for several decades. Tremendous progress in our understanding of cancer and viruses, combined with breakthroughs in DNA engineering, has enabled Jennerex to engineer our oncolytic viral therapies to achieve maximum safety and efficacy, and this is now being borne out in human clinical trials. Targeted oncolytic poxviruses for cancer hold significant commercial and medical potential and represent a breakthrough technology for cancer. The primary reasons are their enhanced tolerability and efficacy versus currently available treatments such as chemotherapy. First, these products are highly selective for cancer and therefore have minimal side effects (flu-like symptoms). In addition, their efficacy is driven by three, novel mechanisms of action: 1) Rapid de-bulking of tumors via direct killing of tumor cells 2) Activation of an antivascular effect with rapid tumor vascular knockout and 3) Induction of a durable immune response. Of note, these mechanisms are non-cross resistant with other approved available therapies. Therefore, these products have the potential to treat tumors that have failed all other available therapies. In addition, given their novel mechanisms of action, these products can also be combined with other complementary therapies in order to get patients the best aspects of each product.

Product candidates from the SOLVE platform exploit the unique characteristics of vaccinia, including its stealth EEV form, which allows the virus to survive in the bloodstream in the presence of neutralizing antibodies, leading to its ability to be administered both intravenously (IV) and intratumorally (IT). The ability to deliver these products intravenously in order to achieve systemic efficacy represents a significant advance for the field of oncolytic immunotherapy. In August 2011, we published clinical data in the journal, Nature, proving the ability of Pexa-Vec to be delivered tumors effectively and safely via intravenous administration. Data summarize in this publication showed that normal tissues were not significantly affected clinically, underscoring the designed selectivity of Pexa-Vec for malignant tissue and safety of the product. Subsequent clinical studies have shown the ability to achieve effective dosing levels on repeated intravenous administrations despite the presence of neutralizing antibodies.

How does it work?
Animation of product
mechanism of action